Mergers & Acquisitions (M&A) garner headlines and lead to big returns for the right investors, but they can often be a bit of a crapshoot, especially in the Pharmaceutical industry. SA author Biosci Capital Partners makes the case in two articles that Crispr Therapeutics, a pioneer of gene editing technologies, might be a target for Gilead Sciences. Behind The Idea breaks down the case and discusses how to deal with the hope of a big payout and the risk that it won't happen.<br />Learn more about your ad choices. Visit megaphone.fm/adchoices

Mergers & Acquisitions (M&A) garner headlines and lead to big returns for the right investors, but they can often be a bit of a crapshoot, especially in the Pharmaceutical industry. SA author Biosci Capital Partners makes the case in two articles that Crispr Therapeutics, a pioneer of gene editing technologies, might be a target for Gilead Sciences. Behind The Idea breaks down the case and discusses how to deal with the hope of a big payout and the risk that it won't happen.Learn more about your ad choices. Visit megaphone.fm/adchoices

Mergers &amp; Acquisitions (M&amp;A) garner headlines and lead to big returns for the right investors, but they can often be a bit of a crapshoot, especially in the Pharmaceutical industry. SA author Biosci Capital Partners makes the case in two articles that Crispr Therapeutics, a pioneer of gene editing technologies, might be a target for Gilead Sciences. Behind The Idea breaks down the case and discusses how to deal with the hope of a big payout and the risk that it won't happen.<br>Learn more about your ad choices. Visit megaphone.fm/adchoices

Behind The Idea #5: Gilead's Hunt And The Crispr Crapshoot

On Behind The Idea, Seeking Alpha editors Mike Taylor and Daniel Shvartsman take a closer look at an investment idea published on Seeking Alpha to see what makes for compelling investing analysis. We look at what’s happening with the underlying company, what the author’s case is, how well s/he made that case, and what we can learn from this investment story. We also bring on the authors, top investors, and industry analysts or experts to explore the case further. We hope the breakdowns and discussions are is both timely and evergreen, educational and entertaining for investors.

Share Behind The Idea #5: Gilead's Hunt And The Crispr Crapshoot

Sign up to save your podcasts

Behind The Idea #5: Gilead's Hunt And The Crispr Crapshoot

Behind The Idea #5: Gilead's Hunt And The Crispr Crapshoot

More shows like Behind The Idea

SA For FAs

Wall Street Breakfast

Marketplace Roundtable

The Cannabis Investing Podcast

Let's Talk ETFs

Alpha Trader